Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian equity mkts back in green
Thu, 7 Feb 11:30 am

Indian equity markets have been back in green during the previous two hours of trade. The most noticeable upward movements have been witnessed in the software and auto sectors while metal and consumer durables have faced the maximum selling pressures.

The BSE-Sensex is up by 35 points and NSE-Nifty is up by 11 points. BSE Mid Cap index and BSE Small Cap index are trading higher by 0.47% and 0.44% respectively. The rupee is trading at 53.32 to the US dollar.

Large software stocks are trading on a mixed note with Mahindra Satyam and Tech Mahindra leading the gains while Info Edge and Moser Baer India are facing the most selling pressures. According to a leading financial daily, the management of Wipro and Infosys have engaged the consultancy and audit firm, Ernst & Young to reviews their current HR practices and the internal procedures within HR in order to protect themselves from legal problems that they have faced overseas recently. The need to reassess internal procedures has come about after a series of incidents in which the carelessness and ignorance of the large software companies, including Wipro and Infosys have been exposed.

Infosys is fighting allegations that it broke visa rules while sending engineers to the US. It is further envisaged that once E&Y's audit with respect to the existing procedures is complete, the consultancy's legal experts in each of the foreign locations would devise new procedures to make Wipro and Infosys fully compliant with the local laws. While most of the current troubles tend to be around sending employees to the US, in the near future, the same could be true for other markets as well. Wipro's share is trading up by 0.20% and Infosys's share is trading up by 0.59%.

Indian pharma stocks are also trading on a mixed note with Ranbaxy and Wockhardt leading the gains while Zandu realty ltd. and Strides Arcolab are leading the losses. Ranbaxy's shares have fallen by over 18% in the last month following its recall of the cholesterol lowering drug, Lipitor from the US in November 2012. Lipitor is a generic drug and the company was expected to restore supplies post the recall, however, it failed to do so in the indicated time frame of December 2012. The Company earlier indicated its objective of meeting the deadline, but after more than a month's delay in resupplying the drug in the worlds' biggest drug market, questions are being raised on the Company's efficiency and on the generic product, Lipitor with obvious negative impact on the Company's share price.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity mkts back in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.